PTX - Pernix Therapeutics Holdings, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue140,856175,850121,747
Cost of Revenue43,32051,40847,965
Gross Profit97,536124,44273,782
Operating Expenses
Research Development6,0798,2293,938
Selling General and Administrative143,360121,63567,059
Non Recurring2,2871,1371,137
Others86,13894,69532,999
Total Operating Expenses237,864225,696-
Operating Income or Loss-140,328-101,254-30,214
Income from Continuing Operations
Total Other Income/Expenses Net9,034-1,722353
Earnings Before Interest and Taxes-131,294-102,976-29,861
Interest Expense37,85738,27719,150
Income Before Tax-169,151-141,253-49,011
Income Tax Expense4397,062-13,725
Minority Interest---
Net Income From Continuing Ops-169,590-148,315-35,286
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-169,590-148,315-35,286
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-169,590-148,315-35,286